Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.905 USD | +0.79% | -53.32% | +22.57% |
Financials (USD)
Sales 2024 * | 110M | Sales 2025 * | 72.48M | Capitalization | 128M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -52M | EV / Sales 2024 * | 1.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.77 x |
P/E ratio 2024 * |
-12.6
x | P/E ratio 2025 * |
-3.81
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -4.55% | ||
1 week | -56.75% | ||
Current month | +15.95% | ||
1 month | -12.09% | ||
3 months | +34.04% | ||
6 months | +53.66% | ||
Current year | +21.94% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 1.9 | +0.53% | 3 993 947 |
24-05-13 | 1.89 | -4.55% | 6,114,521 |
24-05-10 | 1.98 | -2.94% | 12,154,821 |
24-05-09 | 2.04 | -51.31% | 41,562,499 |
24-05-08 | 4.19 | +2.95% | 40,523,342 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.94% | 128M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.24% | 21.93B | |
-12.15% | 22.34B | |
-5.61% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- CTMX Stock